Study Reveals Stard7's Dual Role in Intestinal Cancer Development

Colon cancer kills more people each year than almost any other malignancy — it is the third most commonly diagnosed cancer on earth and the second leading cause of cancer-related death. Yet the molecular machinery that drives it remains, in many places, poorly mapped. A team at the University of Liège has now charted one unexpected corner of that machinery, and what they found upends a decade of assumptions about a protein called Stard7.

For years, Stard7 was considered a bit player — a lipid courier whose main job was shuttling fats into mitochondria, the energy-generating structures inside every cell. Without that lipid supply, mitochondria lose their shape and slow down. Interesting, perhaps, but not obviously connected to cancer. The Liège researchers, working out of the GIGA Medical Chemistry Laboratory, suspected there was more to the story.

To find out, they engineered mice in which the gene responsible for producing Stard7 was switched off exclusively in intestinal cells, leaving every other organ untouched. The precision of that approach mattered: it let them isolate exactly what happens when the intestine loses this one protein. What they found was a cascade of cellular distress. Mitochondria in those cells ran at reduced capacity, generating less energy. In response, the cells began producing elevated levels of free radicals — unstable, chemically reactive molecules that can damage DNA and degrade other cellular components.

Facing that internal stress, the cells reorganized. They shifted their fat composition and activated two powerful molecular regulators. The first, mTORC1, is a growth promoter; when it switches on, cells begin to multiply. The second, ATF4, is a stress-response switch that redirected the affected cells toward producing serine — an amino acid that cancer cells are known to use as a preferred fuel for growth and survival. Taken together, these changes created a cellular environment primed for tumor formation.

Then came the study's most striking finding. The team tested Stard7 deficiency in two different cancer models, and the protein behaved in opposite ways depending on which one they used. In a model driven by chronic intestinal inflammation — the kind of environment seen in patients with inflammatory bowel disease — removing Stard7 actually reduced tumor development. In that context, the protein was acting as an accelerant, and its absence was protective.

But in a second model, one that replicates the most common form of human colon cancer — triggered by a mutation in a gene called APC, which normally restrains cell proliferation — the opposite was true. There, Stard7 deficiency accelerated tumor growth. The protein, in that setting, had been functioning as a brake. Remove it, and the disease moves faster. As Alain Chariot, one of the researchers, put it: Stard7 can act as either a brake or an accelerator depending on the mutational identity of the tumor.

The second model produced something of immediate practical value: a new mouse strain carrying both an APC mutation and intestinal Stard7 deficiency. These animals rapidly develop multiple tumors in the distal colon — the section most commonly affected in human patients — making them unusually faithful stand-ins for the human disease. The model has another notable feature: the gut microbiome composition in these mice resembles what is observed in human colorectal cancer patients, opening a window onto the still-murky relationship between microbial imbalance, mitochondrial dysfunction, and tumor development.

What the Liège study ultimately illustrates is a core tension in modern oncology. Cancer is not one disease but many, and a protein that protects one patient may harm another depending on the genetic context of their tumor. Chariot's team is explicit about the implication: before any treatment targeting Stard7 could be considered, clinicians would need a precise molecular portrait of the individual tumor in question. That is the promise — and the demand — of personalized medicine.

The research lays groundwork rather than delivering a cure, but groundwork is what the field needs. A realistic animal model, a clearer picture of how mitochondrial stress feeds tumor growth, and a protein whose dual nature now demands closer attention — these are the tools the next round of researchers will pick up.